LIXTE BIOTECHNOLOGY HOLDINGS, INC.
Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) is a clinical-stage pharmaceutical company developing a new class of oncology treatments and cancer therapies called PP2A inhibitors.
Funding history
About LIXTE BIOTECHNOLOGY HOLDINGS, INC.
How much funding has LIXTE BIOTECHNOLOGY HOLDINGS, INC. raised?
LIXTE BIOTECHNOLOGY HOLDINGS, INC. has raised $3.5M in total funding. The most recent round was Series B.
Where is LIXTE BIOTECHNOLOGY HOLDINGS, INC. headquartered?
LIXTE BIOTECHNOLOGY HOLDINGS, INC. is headquartered in Pasadena, CA.
What does LIXTE BIOTECHNOLOGY HOLDINGS, INC. do?
Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) is a clinical-stage pharmaceutical company developing a new class of oncology treatments and cancer therapies called PP2A inhibitors.
What problem does LIXTE BIOTECHNOLOGY HOLDINGS, INC. solve?
Chemotherapy and immunotherapy are limited by cancer cell resistance and treatment-limiting toxicity, which restrict dosage/duration and overall efficacy.
What's LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s solution?
Lixte is developing PP2A inhibitors, led by molecule LB-100, designed to enhance the efficacy of both chemotherapy and immunotherapy.
What makes LIXTE BIOTECHNOLOGY HOLDINGS, INC. different?
LB-100 is described as a first-in-class enhancer of chemo/immunotherapy, with preclinical synergy data and an active clinical trial in ovarian clear cell carcinoma supported by GSK at MD Anderson Cancer Center; the company is Nasdaq-listed (LIXT).
What makes LIXTE BIOTECHNOLOGY HOLDINGS, INC. notable?
Lixte Biotechnology was founded by John Kovach, MD, and its scientific team includes René Bernards, PhD, a prominent researcher in molecular carcinogenesis.
Leadership
❝ Cite this page
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated August 26, 2026.